Changes of the serum levels of Apelin and Cystatin C in type 2 diabetic patients with nephropathy and its clinical significance.

doi:10.3877/cma.j.issn.2095-9605.2021.02.002

Abstract

Abstract:

Objective

To analyze the correlation between the peripheral blood levels of Apelin and Cystatin C (Cys-C) in type 2 diabetic patients with nephropathy and its clinical significance.

Methods

Sixty-three patients with type 2 diabetes mellitus treated in the Endocrinology and Cadre ward of the People’s Hospital of Guangxi Zhuang Autonomus Region from May 2014 to February 2017, were divided into diabetic nephropathy patients group (24 hours urine micro albumin >30 mg/24h, n=31) and non-diabetic nephropathy group (24 hours urine micro albumin≤30 mg/24h, n=32) according to the 24 hours urine micro albumin. And 30 healthy individuals were enrolled as nomal contol group. The fasting serum Apelin level and whole blood Cys-C level were measured and were compared among the three groups. The correlation of Apelin level with Cys-C level was analyzed in the diabetic nephropathy group.

Results

The Apelin and Cys-C levels in diabetic nephropathy group, the non-diabetic nephropathy group were significantly higher than those in normal control group (P<0. 05). The Apelin and Cys-C levels derreased in diabetic nephropathy group were significantly higher than those the non-diabetic nephropathy group (P<0.05). The Apelin level positively comelated with the Cys-C level in the diabetic nephropathy group (P<0.05).

Conclusions

There existed a positive correlation between the levels of Apelin and Cys-C in the type 2 diabetic patients with nephropathy, considering that both of them regulat the development of disease through the synergistic in glomerulus, which can be an early indicator of diabetic nephropathy.

Key words: Diabetic nephropathy, Cystatin C, Apelin

Donglian Yang, Luwen Chen, Ruiping Yang. Changes of the serum levels of Apelin and Cystatin C in type 2 diabetic patients with nephropathy and its clinical significance.[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2021, 07(02): 77-80.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfpydxbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9605.2021.02.002

https://zhfpydxbdzzz.cma-cmc.com.cn/EN/Y2021/V07/I02/77

Figures/Tables 1

References 19

[15]	魏倩, 张锦. 2型糖尿病肾病不同时期的胰岛素抵抗分析 [J]. 中国中西医结合肾病杂志, 2010, 11(1): 50-52.
[16]	Mehmet GS, Hakan MT, Osman , et a1. Plasma Apelin 1evels in diabetic patients with and without neuropathy [J]. Central European Journal of Medicine, 2009, 4(2): 241-244．
[17]	张剑平, 刘晓娟, 董文成, 等. 血清Cys-C、apelin水平与妊娠期糖尿病的相关性分析 [J]. 临床合理用药, 2015, 12(80): 169-170.
[18]	陈伟, 黎英荣, 杨冬莲, 等. 2型糖尿病肾病患者血清Apelin水平变化的研究[J]. 广西医科大学学报, 2012, 29(6): 908-909.
[19]	Zhang BH, Wang W, Wang H, et a1. Promoting effect s of the adipokine,apelin,on diabetic nephrepathy [J]. PLoS One, 2013, 8(4): 60457.
[1]	黄俊, 王永红, 马华兰. 血清胱抑素Ｃ、β2微球蛋白、尿微量白蛋白联合检测在糖尿病肾病早期诊断中的临床价值 [J]. 中国卫生检验杂志, 2017, 27(1): 54-56.
[2]	刘敏, 娄占本, 古丽鲜·热依木, 等. 尿清蛋白排泄率与血浆同型半胱氨酸在糖尿病肾病诊疗中的价值 [J]. 现代检验医学杂志, 2014, 29(3): 158-159.
[3]	Boucher J, Masri B, Daviaud D, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity [J]. Endocrinology, 2005, 146(4): 1764-1771.
[4]	Stehouwer CD, Gall MA, Twisk JW, et al. Increased urinary albuminexcretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death [J]. Diabetes, 2002, 51(4): 1157-1165.
[5]	Navarro JF, Mora C. Role of inflammation in diabetic complications [J]. Nephrol Dial Transplant, 2005, 20(12): 2601-2604.
[6]	Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor [J]. Circulation, 2004, 109(21): 2-10.
[7]	World Health Organization. Definition diagnosis and classification of diabetes mellutus and its complications: report of a World Health Organisation Collaborations [J]. Diabet Med, 1999, 15(7): 539-553.
[8]	龚江, 许茜, 冯泳涛, 等. 2型糖尿病肾病患者血清Cys-C、ADPN、hs -CRP和HCY表达的临床意义 [J]. 检验医学与临床, 2017, 14(10): 1405-1406, 1409.
[9]	朱文芳, 沈建军, 韩双, 等. 血清NGAL、Cys-C、RBP联合检测对糖尿病肾损伤早期诊断的临床意义 [J]. 海南医学, 2017, 28 (19): 3169-3171.
[10]	张剑平, 刘晓娟, 董文成, 等．血清IL-6、MCP-1、Cys-C、apelin水平与妊娠期糖尿病的相关性分析 [J]. 临床合理用药, 2015, 10(8): 153-154.
[11]	Aghadavod E, Khodadadi S, Baradaran A, et al. Role of oxidative stress and inflammatory factors in diabetic kidney disease [J]. Iran J Kidney Dis, 2016, 10(6): 337-343.
[12]	Tatemoto K, Hosoya M, Habata Y, et a1. Isolation and characterization of a novel endogenous peptide Iigand for the human APJ receptor [J]. Biochem Biophys Res Commun, 1998, 251(2): 471-476．
[13]]	Galanth C, Hus-Citharel A, Li B, et al. Apelin in the control of body fluid homeostasis and cardiovascular functions [J]. Curr Pharm Des, 2012, 18(6): 789-798.
[14]	Kleinz MJ, Davenport AP. Immunocytoechernical localization of the endogenous vasoactive peptide Apelin to human vascular and endocardial endothelial cells [J]. Regulatory Peptides, 2004, 118(3): 119-125.

组别	例数（n）	Apelin（pg/mL）	CysC（mg/L）
糖尿病肾病组	31	427.6±50.2^＃,*	1.28±0.44^＃,*
糖尿病非肾病组	32	392.5±37.3^＃	0.91±0.14^＃
正常对照组	30	358.9±56.2	0.76±0.16
F值		15.379	32.270
P值		<0.05	<0.05

组别	例数（n）	Apelin（pg/mL）	CysC（mg/L）
糖尿病肾病组	31	427.6±50.2^＃,*	1.28±0.44^＃,*
糖尿病非肾病组	32	392.5±37.3^＃	0.91±0.14^＃
正常对照组	30	358.9±56.2	0.76±0.16
F值		15.379	32.270
P值		<0.05	<0.05

Please choose a citation manager

Content to export